Drug industry fails to win judicial review of new UK cost curbs

LONDON (Reuters) - Britain's pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 million) annually no longer get automatic funding.